###begin article-title 0
Loss of Anti-Bax Function in Gerstmann-Straussler-Scheinker Syndrome-Associated Prion Protein Mutants
###end article-title 0
###begin p 1
Conceived and designed the experiments: JJ ACL. Performed the experiments: JJ MM PM PNG JH ACL. Analyzed the data: JJ MM PM PNG JH ACL. Contributed reagents/materials/analysis tools: CGG ACL. Wrote the paper: JJ MM PM PNG CGG ACL.
###end p 1
###begin p 2
###xml 464 465 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 673 674 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 681 682 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 700 701 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 729 730 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 737 738 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 748 749 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 759 760 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 983 984 983 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 612 617 <span type="species:ncbi:9606">human</span>
Previously, we have shown the loss of anti-Bax function in Creutzfeldt Jakob disease (CJD)-associated prion protein (PrP) mutants that are unable to generate cytosolic PrP (CyPrP). To determine if the anti-Bax function of PrP modulates the manifestation of prion diseases, we further investigated the anti-Bax function of eight familial Gerstmann-Straussler-Scheinker Syndrome (GSS)-associated PrP mutants. These PrP mutants contained their respective methionine (M) or valine (V) at codon 129. All of the mutants lost their ability to prevent Bax-mediated chromatin condensation or DNA fragmentation in primary human neurons. In the breast carcinoma MCF-7 cells, the F198SV, D202NV, P102LV and Q217RV retained, whereas the P102LM, P105LV, Y145stopM and Q212PM PrP mutants lost their ability to inhibit Bax-mediated condensed chromatin. The inhibition of Bax-mediated condensed chromatin depended on the ability of the mutants to generate cytosolic PrP. However, except for the P102LV, none of the mutants significantly inhibited Bax-mediated caspase activation. These results show that the cytosolic PrP generated from the GSS mutants is not as efficient as wild type PrP in inhibiting Bax-mediated cell death. Furthermore, these results indicate that the anti-Bax function is also disrupted in GSS-associated PrP mutants and is not associated with the difference between CJD and GSS.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 110 113 110 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Collins1">[1]</xref>
###xml 365 368 365 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Ghetti1">[2]</xref>
###xml 369 372 369 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gambetti1">[4]</xref>
###xml 567 570 567 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gambetti1">[4]</xref>
###xml 991 994 991 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Goldfarb1">[3]</xref>
###xml 996 999 996 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gambetti1">[4]</xref>
###xml 1138 1141 1138 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Medori1">[5]</xref>
###xml 1342 1345 1342 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Ghetti1">[2]</xref>
###xml 1347 1350 1347 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Bugiani1">[6]</xref>
###xml 1464 1467 1464 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Collins1">[1]</xref>
Autosomal dominant inherited prion protein (PrP) gene mutations cause approximately 10% of all prion diseases [1]. Eleven different single point mutations are associated with Creutzfeldt-Jakob disease (CJD), eight different single point mutations are associated with Gerstmann-Straussler-Scheinker (GSS), and the D178N mutation causes Fatal Familial Insomnia (FFI) [2]-[4]. Each mutation is specifically associated with either a methionine or a valine polymorphic amino acid at codon 129, which can severely affect the type, the onset and the duration of the disease [4]. While each of the PrP single point mutations is sufficient for neurodegeneration, the onset and duration of disease, the area of the brain affected and the pathology associated with neurodegeneration distinguish each of these diseases. CJD, characterized by spongiform encephalopathy, astrogliosis, and proteinase K resistant PrP in the cerebral cortex, generates a rapidly progressing dementia in affected individuals [3], [4]. FFI affects the ventral thalamic area and the primary symptoms are insomnia followed by a rapidly progressing dementia of short duration [5]. GSS, characterized by astrogliosis, proteinase K resistant PrP, PrP-plaques, and sometimes spongiform encephalopathy and neurofibrillary tangles, is associated with ataxia and/or spastic paraparesis [2], [6]. GSS occurs in the fifth or sixth decade of life and, in contrast to CJD, the progression of the disease is slow [1].
###end p 4
###begin p 5
The underlying molecular mechanism of prion diseases associated with each of these mutations is unclear. Gain of function is suspected as the cause of the disease. However, while the mutant proteins are expressed throughout the lifespan of the individual, disease rarely develops before the fourth or fifth decade of life, indicating that misfolding of PrP caused by the mutation is not sufficient to initiate the neurodegeneration. This prompted us to investigate if loss of function could be involved in the length and severity of disease progression.
###end p 5
###begin p 6
###xml 125 128 125 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou1">[7]</xref>
###xml 130 133 130 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Westergard1">[8]</xref>
###xml 248 251 248 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Coulpier1">[9]</xref>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Walz1">[13]</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-DiarraMehrpour1">[14]</xref>
###xml 434 438 434 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Meslin1">[17]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou2">[18]</xref>
###xml 603 607 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Bounhar1">[20]</xref>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-White1">[21]</xref>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Leber1">[22]</xref>
###xml 1222 1226 1222 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Shi1">[23]</xref>
###xml 1450 1454 1450 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Li1">[24]</xref>
###xml 1456 1460 1456 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Yu1">[25]</xref>
###xml 1563 1567 1563 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou2">[18]</xref>
###xml 1746 1750 1746 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou3">[19]</xref>
###xml 1752 1756 1752 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Lin1">[26]</xref>
###xml 1987 1991 1987 1991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou3">[19]</xref>
###xml 1993 1997 1993 1997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Drisaldi1">[27]</xref>
###xml 1998 2002 1998 2002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Kang1">[29]</xref>
###xml 2140 2144 2140 2144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-LarochePierre1">[30]</xref>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
While the normal function of PrP is still not entirely clear, there is growing evidence for the neuroprotective roles of PrP [7], [8]. PrP null hippocampal neuronal cell lines and PrP null mice have increased susceptibility to a variety of insults [9]-[13]. Furthermore, recent evidence indicates that PrP prevents cell death in cancer cell types. PrP prevents apoptosis in multidrug-resistant breast and gastric carcinoma cells [14]-[17]. We have reported that the normal cellular prion protein prevents Bax-mediated cell death in primary human neurons and in the breast carcinoma MCF-7 cell line [18]-[20]. Bax, a member of the Bcl-2 family of proteins, is a strong pro-apoptotic protein in neurons [21]. Bax is normally cytosolic or loosely attached to mitochondria but, in cells submitted to apoptotic insults, Bax undergoes a change in conformation, oligomerisation, translocation to the mitochondria and then induces the release of apoptogenic factors from the mitochondria into the cytosol [22]. The release of cytochrome c in the cytosol activates the apoptosome, resulting in Caspase-9 (Casp9) and Caspase-3 (Casp3) activation and caspase-dependent DNA fragmentation into 180 bp fragments and condensed chromatin [23]. The mitochondria-released apoptosis inducing factor (AIF) and endonuclease G (Endo G) directly translocate to the nucleus and activate caspase-independent DNA fragmentation in large 50 Kb fragments and condensed chromatin [24], [25]. PrP prevents the conformational change of Bax and thus acts at the very first step of Bax activation [18]. While most of the PrP accumulates on the cell surface as a GPI-anchored protein, it is the smaller amount of cytosolic PrP (CyPrP) that is responsible for the anti-Bax function [19], [26]. CyPrP can arise from either retrotranslocation of PrP from the secretory pathway or via a failure of PrP's signal peptide to integrate into the endoplasmic reticulum during protein synthesis (pre-emptive quality control pathway) [19], [27]-[29]. Moreover, the anti-Bax function of PrP is situated within helix 3 of PrP, the area with the most single point mutations in PrP diseases [30].
###end p 6
###begin p 7
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 307 312 <span type="species:ncbi:9606">human</span>
We previously showed that the GSS-associated A117V PrP mutant with a valine at codon 129 retained the anti-Bax function while all of the 11 CJD-associated PrP mutations carrying a methionine at codon 129 or the FFI-associated D178N PrP mutant lost the ability to prevent Bax-mediated condensed chromatin in human neurons [31]. Considering that GSS disease has a slower progression and a later onset compared to CJD, we investigated whether all other GSS-associated PrP mutants retained the anti-Bax function.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
Cell cultures
###end title 9
###begin p 10
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-LeBlanc1">[32]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-LarochePierre1">[30]</xref>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 155 160 <span type="species:ncbi:10090">Mouse</span>
###xml 189 194 <span type="species:ncbi:9606">human</span>
Cultures of human primary neurons were done as previously described under the ethical approval from the McGill University Institutional Review Board [32]. Mouse neuroblastoma N2a cells and human MCF-7 breast carcinoma cells were obtained from The American Type Culture Collection (Manassas, VA, USA) and cultured as described previously [30].
###end p 10
###begin title 11
###xml 38 43 <span type="species:ncbi:9606">human</span>
Cloning, site-directed mutagenesis of human PrP, and sequencing of PrP mutants
###end title 11
###begin p 12
###xml 176 177 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 202 203 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 316 317 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 324 325 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 352 353 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 380 412 380 412 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGGGGAGAACTCCACCGAGACCGAC-3&#8242;</named-content>
###xml 421 461 421 461 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAACTTCACCGAGACCAACGTTAAGATGATGGAG-3&#8242;</named-content>
###xml 470 511 470 511 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGATGTGTAT CACCCGGTACGAGAGGGAATCTC-3&#8242;</named-content>
###xml 520 559 520 559 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTCAGTGGAACAAGCTGAGTAAGC CAAAAACC-3&#8242;</named-content>
###xml 568 612 568 612 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAACAAGCCGAGTAAGCTAAAAACCAACATGAAGCAC-3&#8242;</named-content>
###xml 624 660 624 660 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCAGTGACTAGGAGGATCGTTACTATCG-3&#8242;</named-content>
###xml 673 701 673 701 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCGTGGTTGAGCC GATGTGTATCACCC</named-content>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 1178 1182 1170 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou2">[18]</xref>
###xml 1235 1238 1227 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sca</italic>
###xml 1245 1248 1237 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xba</italic>
###xml 1001 1004 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
GSS-associated mutations were produced by QuikChange Site-Directed Mutagenesis (Invitrogen, Burlington, ON, Canada) from the pcDNA3.1(+)-PrP wild type carrying a valine (WT PrPV) or a methionine (WT PrPM) at the polymorphic codon 129 [31]. Forward primers used to produce PrP mutants P102LM, P102LV, P105LV, Y145stopM, F198SV, D202NV, Q212PM, and Q217RV are the following: F198S, 5'-AGGGGGAGAACTCCACCGAGACCGAC-3'; D202N, 5'-GAACTTCACCGAGACCAACGTTAAGATGATGGAG-3'; Q217R, 5'-CAGATGTGTAT CACCCGGTACGAGAGGGAATCTC-3'; P102L, 5'-GTCAGTGGAACAAGCTGAGTAAGC CAAAAACC-3'; P105L, 5'-GGAACAAGCCGAGTAAGCTAAAAACCAACATGAAGCAC-3'; Y145stop, 5'-CGGCAGTGACTAGGAGGATCGTTACTATCG-3'; and Q212P, GCGTGGTTGAGCC GATGTGTATCACCC. All PrP mutations were confirmed by sequencing using the Sequenase Version 2.0 DNA Sequencing kit (USB, Cleveland, OH, USA) and the polymorphism at codon 129 was confirmed by PCR [31]. As previously done for WT PrP, PrP mutant cDNAs were PCR amplified and cloned downstream of the cytomegalovirus (CMV) promoter of the pBudCE4.1 bigenic vector containing the enhanced green fluorescent protein (EGFP) or EGFP-Bax cDNAs under the elongation factor 1alpha (EF-1alpha) promoter [18]. The PCR amplified PrP mutants were cloned into the Sca I and Xba I sites of pBud-EGFP or pBud-EGFP-Bax generating pBud-EGFP/PrP mutants or pBud-EGFP-Bax/PrP mutants.
###end p 12
###begin title 13
Transfections
###end title 13
###begin p 14
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 369 373 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou2">[18]</xref>
###xml 375 379 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 398 399 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 523 527 515 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2000</sup>
###xml 667 671 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Drisaldi1">[27]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 265 270 <span type="species:ncbi:9606">human</span>
Human neurons (1.5x105 cells) plated onto poly-L-lysine-coated plastic coverslips and MCF-7 cells (2.5x105 cells) plated onto glass coverslips were transfected with the Helios Gene Gun system (Bio-Rad, Mississauga, ON, Canada) at a shooting pressure of 100 psi for human neurons and 220 psi for MCF-7 cells. Cartridges contained 1 microg DNA and 0.125 mg gold per shot [18], [31]. N2a cells (0.8x106 cells) plated in six-well plates were transfected with 4 microg of pBud-EGFP/PrP or/PrP mutant DNAs using the Lipofectamine2000 reagent (Invitrogen). To generate SP-CyPrP, N2a cells were transfected with 10 and 20 microg of pBud-EGFP/PrP DNA, as previously described [27].
###end p 14
###begin title 15
Condensed chromatin
###end title 15
###begin p 16
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 165 166 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 169 170 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Twenty hours after transfection, MCF-7 cells and human neurons were washed with phosphate-buffered saline (PBS, 150 mM NaCl, 2.7 mM KCl, 1.3 mM KH2PO4, and 8.1 mM Na2HPO4, pH 7.4), fixed 20 min at room temperature in 4% paraformaldehyde and 4% sucrose in PBS, and the chromatin stained 20 min with 1 microg/mL Hoechst 33342 (Sigma-Aldrich, Oakville, ON, Canada) in PBS. The percentage of cell death was calculated by counting the number of EGFP-positive cells with condensed chromatin over the total number of EGFP-positive cells using a Nikon Eclipse TE2000-U microscope.
###end p 16
###begin title 17
TUNEL
###end title 17
###begin p 18
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Situ</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neurons were fixed 20 hours after transfection, as described above, and Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was performed with the TM Red In Situ Cell Death Detection kit (Roche Applied Science, Laval, QC, Canada). The percentage of TUNEL-positive cells was obtained by counting the TUNEL- and EGFP-positive cells over the total number of EGFP-positive cells.
###end p 18
###begin title 19
Caspase activity
###end title 19
###begin p 20
MCF-7 cells were labeled 20 hours after transfection for active caspases with the SR Fluorochrome-labeled inhibitors of caspases (FLICA) poly caspase kit (AbD Serotec, Raleigh, NC, USA). The percentage of FLICA-positive cells was calculated by counting the FLICA- and EGFP-positive cells over the number of total EGFP-positive cells.
###end p 20
###begin title 21
Subcellular Fractionations
###end title 21
###begin p 22
###xml 230 234 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 561 562 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
N2a cells were treated 24 hours after transfection with 0.25 microM epoxomycin (BioMol, Plymouth Meeting, PA, USA) and 5 microg/mL Brefeldin A (BioMol) for 18 hours. Subcellular fractionation was performed as described previously [31] using one well of a six-well plate for each condition. To prepare samples for western blotting, proteins from the homogenate (1/20 of one well), membranes (1/4 of one well), cytosol (1 well), and nuclei (1/4 of one well) were precipitated with four volumes of ice-cold methanol overnight at -20degreesC, centrifuged at 11 500xg 15 min at 4degreesC, dried, and solubilized in the Laemmli's sample buffer (2% SDS (w/v), 5% beta-mercaptoethanol (v/v), 10% glycerol, 0.01% bromophenol blue (w/v), and 62.5 mM Tris-HCl, pH 6.8).
###end p 22
###begin title 23
Detergent solubility of CyPrP
###end title 23
###begin p 24
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
Cytosolic proteins obtained from the subcellular fractions were solubilized 20 min on ice in lysis buffer (150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100 (v/v), 0.5% sodium deoxycholate (NaDOC) (w/v), 50 mM Tris-HCl, pH 7.5) and centrifuged at 11 500xg for 15 min at 4degreesC to separate detergent-soluble proteins (supernatant) from the detergent-insoluble proteins (pellet). Detergent-soluble proteins were concentrated by methanol precipitation and these as well as the detergent insoluble proteins solubilized in the Laemmli's sample buffer for western blotting.
###end p 24
###begin title 25
Peptide-N-glycosidase F digestion
###end title 25
###begin p 26
Membrane fractions from N2a cells were treated with Peptide-N-glycosidase F (PNGase F) according to manufacturer's instructions (New England BioLabs, Pickering, ON, Canada). Briefly, proteins from membrane fractions were adjusted to 0.5% SDS and 1% beta-mercaptoethanol, denatured 10 min at 100degreesC and incubated overnight at 37degreesC with 2 units of PNGase F in the presence of protease inhibitors. The proteins were methanol precipitated as described above.
###end p 26
###begin title 27
Western blot analyses
###end title 27
###begin p 28
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Kascsak1">[33]</xref>
###xml 890 895 <span type="species:ncbi:10090">mouse</span>
###xml 904 910 <span type="species:ncbi:9986">rabbit</span>
###xml 946 957 <span type="species:ncbi:3704">horseradish</span>
The proteins were separated on 15% SDS-PAGE gels and transferred to polyvinylidene fluoride membranes. The membranes were probed with the anti-PrP 3F4 antibody [33] (1:2000), the polyclonal antiserum directed against the N-terminal signal peptide of PrP (SP-PrP, 1:1000, kindly provided by Dr. D.A. Harris, Washington University School of Medicine), the mitochondrial heat shock protein 70 (mtHsp70, 1:10 000, clone JG1; Affinity BioReagents, Golden, CO, USA), CHOP (also called GADD153, 1:1000, clone B-3; Santa Cruz Biotechnology, Santa Cruz, CA, USA), Poly-(ADP-ribose)-polymerase (PARP, 1:2000; Roche Applied Science), Bax (1:1000, Clone N20; Santa Cruz Biotechnology), BiP (also called GRP 78, 1:250, clone H-129; Santa Cruz Biotechnology), GFP (1:1000, clone B-2; Santa Cruz Biotechnology), and beta-actin (1:1000, clone AC-15; Sigma-Aldrich). Immunoreactivity was detected with anti-mouse or anti-rabbit secondary antibodies conjugated to horseradish peroxidase (GE Healthcare, Baie d'Urfe, QC, Canada) and chemiluminescence reagents (Millipore, Billerica, MA, USA).
###end p 28
###begin title 29
Quantitation of cytosolic and nuclear PrP
###end title 29
###begin p 30
The intensity of PrP detected by western blot analyses was resolved with the Image Quant TL software (GE Healthcare). The ratio of cytosolic PrP over membrane PrP or the ratio of nuclear PrP over membrane PrP was calculated.
###end p 30
###begin title 31
Statistical analyses
###end title 31
###begin p 32
###xml 174 182 174 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 339 340 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 344 345 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">z</italic>
Statistical analyses were performed with StatView software (SAS Institute, Cary, NC, USA). To determine the statistically significant difference, we used ANOVA followed by a post hoc Scheffe test. A p value</=0.05 was considered a significant difference. To determine the correlation coefficient and its significance, we used the Fisher's r to z transformation.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M,</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
GSS-associated PrP mutants F198SV, D202NV, P102LV and Q217RV, but not P102LM, P105LV, Y145stopM, and Q212PM, prevent Bax-mediated condensed chromatin in MCF-7 cells
###end title 34
###begin p 35
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Collins1">[1]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Goldfarb1">[3]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Ghetti2">[34]</xref>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Piccardo1">[36]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Ghetti2">[34]</xref>
###xml 562 569 562 569 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1A</bold>
###xml 562 569 562 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g001"><bold>Fig. 1A</bold></xref>
###xml 978 985 974 981 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1B</bold>
###xml 978 985 974 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g001"><bold>Fig. 1B</bold></xref>
###xml 1041 1042 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1058 1059 1054 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1182 1183 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1190 1191 1186 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1201 1202 1197 1198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1212 1213 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1315 1316 1311 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1323 1324 1319 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1335 1336 1331 1332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1363 1364 1359 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1539 1540 1535 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1586 1590 1582 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Hachiya1">[37]</xref>
###xml 1669 1676 1665 1672 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1B</bold>
###xml 1669 1676 1665 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g001"><bold>Fig. 1B</bold></xref>
###xml 548 551 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
GSS-associated PrP mutations P105L, A117V, F198S, D202N, and Q217R have been reported with a valine at codon 129, whereas P102L, Y145stop, and Q212P carry a methionine at codon 129 [1], [3], [34]-[36]. In some rare cases, P102L is associated with a valine at codon 129 [34]. To assess if the PrP anti-Bax function was altered in GSS mutants, specific single point mutations with their respective methionine or valine at codon 129 into the prion protein cDNA were produced and the mutant cDNA inserted into the bigenic pBudCE4.1 construct under the CMV promoter (Fig. 1A). This construct also expresses either EGFP or EGFP-Bax protein under the EF-1alpha promoter. Therefore, cell death is specifically induced by over-expression of Bax and the anti-Bax function of co-expressed wild type (WT) PrP or PrP mutants is directly assessed. Bax overexpression resulted in the condensation of chromatin in approximately 65% of the transfected MCF-7 cells within 20 hrs of transfection (Fig. 1B). Co-expression of WT PrP with either a methionine (PrPM) or valine (PrPV) at codon 129 prevented Bax-mediated condensed chromatin. Similar to our previous observations with CJD mutants, the P102LM, P105LV, Y145stopM and Q212PM PrP mutants completely lost their ability to prevent Bax-mediated condensed chromatin. However, F198SV, D202NV, and Q217RV completely while the P102LV partially retained the anti-Bax function. None of the GSS-associated PrP mutants co-expressed with EGFP induced chromatin condensation in MCF-7 cells, except for the Y145stopM which, consistent with previous observations [37], significantly increased the number of cells with condensed chromatin by 15% (Fig. 1B). Together, these results indicate that only a few of the GSS-associated mutants retain PrP's ability to prevent Bax-mediated condensed chromatin in MCF-7 cells.
###end p 35
###begin title 36
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M,</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
GSS-associated PrP mutants F198SV, D202NV, P102LV and Q217RV, but not P102LM, P105LV, Y145stopM, and Q212PM, prevent Bax-mediated condensed chromatin in MCF-7 cells.
###end title 36
###begin p 37
###xml 548 549 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 564 565 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 752 753 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 24 29 <span type="species:ncbi:9606">human</span>
A. Schematic diagram of human PrP showing the signal peptide, the octapeptide repeats, the transmembrane domain (TM), the beta-sheets (beta1 and beta2), the alpha-helices (alpha1, alpha2, alpha3), the glycosyl phosphatidylinositol (GPI)-anchor signal peptide, the polymorphic codon at amino acid 129, and the GSS PrP mutations. B. Percentage of cell death assessed by condensed chromatin in MCF-7 cells transfected with pBud-EGFP or pBud-EGFP-Bax (control), pBud-EGFP/PrP or PrP mutants, and pBud-EGFP-Bax/PrP or PrP mutants carrying a methionine (M) or a valine (V) at codon 129. Data represent the mean+/-SEM of six independent experiments. At least 600 cells were counted for each condition. * and # indicate a statistically significant difference (p</=0.05) compared to the control and wild type PrP, respectively.
###end p 37
###begin title 38
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
GSS-associated PrP mutants F198SV, D202NV, and Q217RV cannot inhibit Bax-mediated caspase activation
###end title 38
###begin p 39
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Kagawa1">[38]</xref>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Wolf1">[39]</xref>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 493 500 493 500 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2A</bold>
###xml 493 500 493 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g002"><bold>Fig. 2A</bold></xref>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 695 696 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 819 826 819 826 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2B</bold>
###xml 819 826 819 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g002"><bold>Fig. 2B</bold></xref>
###xml 873 874 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 884 885 884 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 904 905 904 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 914 915 914 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 978 979 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1055 1062 1055 1062 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2C</bold>
###xml 1055 1062 1055 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g002"><bold>Fig. 2C</bold></xref>
###xml 1130 1131 1130 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1138 1139 1138 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1150 1151 1150 1151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
MCF-7 cells are deficient in Caspase-3 (Casp3) expression because of a deletion in the Casp3 gene and thus cannot undergo DNA fragmentation in apoptotic conditions [38], [39]. Condensed chromatin is dependent on the activation of Casp6 and Casp7 in these cells. To determine if the F198SV, D202NV, and Q217RV PrP mutants completely inhibited Bax-mediated apoptosis or simply delayed condensed chromatin formation, we measured caspase activity with the FLICA pan-caspase substrate, SR-VAD-fmk (Fig. 2A). Bax induced caspase activity in approximately 60% of the cells and WT PrPM and PrPV inhibited caspase activation. However, in contrast to cell death measured by condensed chromatin, only P102LV inhibited caspases activated by EGFP-Bax overexpression. FLICA positive cells did not always contain condensed chromatin (Fig. 2B). In condensed chromatin-positive cells, Q217RV and P102LV, but not the F198SV or D202NV, inhibited Bax-mediated caspase activation. Furthermore, D202NV significantly induced caspase activation in non-condensed chromatin cells (Fig. 2C). These results indicate that the GSS-associated PrP mutants, F198SV, D202NV, and Q217RV, simply delay the condensation of chromatin but do not completely inhibit Bax-mediated apoptotic pathways in MCF-7 cells.
###end p 39
###begin title 40
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
GSS-associated PrP mutants F198SV, D202NV, and Q217RV cannot inhibit Bax-mediated caspase activation.
###end title 40
###begin p 41
###xml 438 439 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
A. Percentage of FLICA positive MCF-7 cells transfected with pBud-EGFP-Bax (control) or pBud-EGFP-Bax/PrP or PrP mutants. B & C. Percentage of FLICA positive and condensed chromatin (B) or FLICA positive and non-condensed chromatin (C) transfected MCF-7 cells. For A-C, data represent the mean+/-SEM of three independent experiments. At least 300 cells were counted for each condition. * indicates a statistically significant difference (p</=0.05) compared to the control.
###end p 41
###begin title 42
Decreased levels of CyPrP correlate with the loss of anti-Bax function in GSS-associated PrP mutants expressed in MCF-7 cells
###end title 42
###begin p 43
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 333 340 333 340 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3A</bold>
###xml 333 340 333 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3A</bold></xref>
###xml 621 625 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 969 973 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Ron1">[40]</xref>
###xml 343 348 <span type="species:ncbi:10090">Mouse</span>
###xml 498 503 <span type="species:ncbi:9606">human</span>
###xml 570 575 <span type="species:ncbi:9606">human</span>
To determine if the loss of anti-Bax function from the GSS-associated PrP mutants is due to lower levels of CyPrP as previously shown in CJD mutants [31], transfected cells treated with Brefeldin A to promote retrotranslocation and epoxomicin to prevent proteasomal degradation of CyPrP, were submitted to subcellular fractionation (Fig. 3A). Mouse N2a cells were used for subcellular fractionations because Brefeldin A and epoxomicin treatment of MCF-7 cells increase the expression of endogenous human PrP and the 3F4 antibody can be used to selectively recognize the human PrP expressed from the transfected construct [31]. The proteins extracted from the membrane, cytosolic, and nuclear fractions showed the presence of mitochondrial Hsp70 (mtHsp70) in the membrane and nuclear fraction only, the presence of the endoplasmic reticulum (ER)-localized BiP protein in the membranes only, and the presence of nuclear protein PARP and nuclear-translocated protein CHOP [40] in the nuclear fraction. Bax was detected in all fractions and EGFP was present in the nuclear and cytosolic, but not in the membrane fractions. The presence of mtHsp70 and Bax in the nuclear fraction, in addition to the nuclear markers PARP and CHOP, indicates either a contamination of the nuclear proteins or a redistribution of these proteins into the nucleus under Brefeldin A and epoxomicin treatment. Nevertheless, these results indicated that the cytosolic and membrane fractions are pure and can thus be used to assess the presence of CyPrP.
###end p 43
###begin title 44
Correlation of the anti-Bax activity with CyPrP levels in GSS-associated PrP mutants.
###end title 44
###begin p 45
###xml 159 160 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 642 643 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 796 797 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 834 835 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 839 840 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">z</italic>
###xml 1108 1109 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
A. Western blot with mitochondrial Hsp70 (mtHsp70), Bip, PARP, CHOP, Bax, GFP, and beta-actin in protein extracts from subcellular fractions from pBud-EGFP/PrPM-transfected N2a cells. Homogenates (H), membrane (M), cytosol (C), and nuclear (N) protein extracts were loaded on gels as a ratio of 1:5:20:5, respectively. B. Western blots of PrP with the 3F4 antibody in proteins extracted from subcellular fractions isolated from pBud-EGFP/PrP or PrP mutant-transfected N2a cells. C. Ratio of CyPrP to membrane PrP. The data represent the mean+/-SEM of three to four independent experiments. * indicates a statistically significant difference (p</=0.05) compared to WT PrP. D. Correlation between the levels of CyPrP and levels of condensed chromatin. The correlation is statistically significant (p</=0.05) as determined by a Fisher's r to z transformation. E. Ratio of nuclear PrP to membrane PrP. The data represent the mean+/-SEM of three to four independent experiments. F. Correlation between the levels of nuclear PrP and levels of condensed chromatin. The correlation is not statistically significant (p = 0.96).
###end p 45
###begin p 46
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 162 169 162 169 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3B</bold>
###xml 162 169 162 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3B</bold></xref>
###xml 417 424 417 424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3C</bold>
###xml 417 424 417 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3C</bold></xref>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 778 785 778 785 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3D</bold>
###xml 778 785 778 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3D</bold></xref>
###xml 886 893 886 893 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3E</bold>
###xml 886 893 886 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3E</bold></xref>
###xml 956 963 956 963 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3F</bold>
###xml 956 963 956 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3F</bold></xref>
The WT PrPM, WT PrPV, F198SV, D202NV, Q217RV and Q212PM PrP mutants generated detectable levels of CyPrP while the P102LM, P102LV, P105LV, and Y145stopM did not (Fig. 3B). The levels of PrP in the membrane, cytosolic and nuclear subcellular fractions were then analyzed quantitatively and the levels of CyPrP were expressed relative to the membrane PrP to account for differences in the levels of protein expression (Fig. 3C). Except for the Q212PM, the mutants generating the highest levels of CyPrP were those inhibiting Bax-mediated condensed chromatin, whereas those with the lowest levels of CyPrP were the ones that had partially or completely lost this function. The level of CyPrP correlated significantly with their ability to prevent Bax-mediated condensed chromatin (Fig. 3D). In contrast, the ratio of nuclear PrP relative to membrane PrP was similar in WT and mutant PrPs (Fig. 3E) and did not correlate with the level of condensed chromatin (Fig. 3F). The results show that reduced CyPrP correlates with loss of PrP's anti-Bax function in MCF-7 cells.
###end p 46
###begin title 47
Glycosylation profile of GSS-associated mutants does not correlate with anti-Bax activity
###end title 47
###begin p 48
###xml 286 293 286 293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3B</bold>
###xml 286 293 286 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g003"><bold>Fig. 3B</bold></xref>
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 366 368 366 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> V</sup>
###xml 375 376 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 379 381 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> V</sup>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 497 498 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 819 825 819 825 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 4</bold>
###xml 819 825 819 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g004"><bold>Fig. 4</bold></xref>
###xml 931 932 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 939 940 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 947 948 947 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 955 956 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 966 967 966 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
Treatment with Brefeldin A prevents maturation of secretory proteins through the Golgi apparatus, therefore only unglycosylated or immature glycosylated forms of PrP were expected in the transfected cells. However, the GSS PrP mutants showed differences in their glycosylation profile (Fig. 3B). In total cellular homogenates or in the membrane fractions, WT PrPM or V, P102LM or V, P105LV, Q217RV showed three PrP immunoreactive protein bands, while F198SV and D202NV generated two, and the Q212PM showed only one. The Y145stopM showed two lower MW protein bands that cannot represent glycosylation since the glycosylation sites are absent in this truncated mutant. To determine if these protein bands reflected glycosylation or truncations of the PrP mutants, the membrane proteins were deglycosylated with PNGase F (Fig. 4). Deglycosylation converted all mutant proteins to the 25 kDa deglycosylated PrP. In addition, the WT PrPM, F198SV, Q217RV, P102LV and P105LV displayed very low levels of some 14-23 kDa MW fragments indicating a small amount of truncated PrP. There was no correlation between the glycosylation profile and the anti-Bax function. These results indicate that the GSS-associated mutants are differentially glycosylated in these transfected cells but that the glycosylation profile does not account for the anti-Bax function of PrP.
###end p 48
###begin title 49
Characterization of the glycosylation profile, detergent solubility and type of CyPrP in GSS mutant-transfected cells.
###end title 49
###begin p 50
###xml 240 241 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 480 481 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 557 558 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
A. Western blots of PrP in membrane fractions from pBud-EGFP/PrP or PrP mutant-transfected cells treated with or without PNGase F. B. Western blot with 3F4 anti-PrP or anti-beta-actin showing detergent solubility of CyPrP from pBud-EGFP/PrPV or PrP mutant-transfected N2a cells. S indicates detergent soluble and I indicates detergent insoluble CyPrP. C. Western blots with anti-SP-CyPrP and beta-actin in cytosolic proteins of N2a cells transfected with 4 microg of pBud-EGFP/PrPV or PrP mutants or transfected with 10 microg and 20 microg of pBud-EGFP/PrPV as positive control for SP-CyPrP detection.
###end p 50
###begin title 51
GSS mutant CyPrPs do not aggregate
###end title 51
###begin p 52
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 297 304 297 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 4B</bold>
###xml 297 304 297 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g004"><bold>Fig. 4B</bold></xref>
To study if CyPrP mutants aggregate, cytosolic proteins from WT PrP or PrP mutant transfected cells were solubilized in 0.5% Triton X-100 and 0.5% sodium deoxycholate. WT PrPV as well as PrP mutants F198SV, D202NV, Q217RV, and Q212PM generated detergent soluble, but no detergent insoluble CyPrP (Fig. 4B). The results show that CyPrP generated from GSS PrP mutants does not aggregate in the cytosol and thus, aggregation cannot be responsible for the loss of anti-Bax function in the GSS mutants that generate CyPrP.
###end p 52
###begin title 53
Transfection of WT PrP and GSS PrP mutants generate some CyPrP through the pre-emptive quality control pathway
###end title 53
###begin p 54
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Drisaldi1">[27]</xref>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 327 328 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 347 348 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 500 507 496 503 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 4C</bold>
###xml 500 507 496 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g004"><bold>Fig. 4C</bold></xref>
To determine if CyPrP generated from GSS PrP mutants occurs through the pre-emptive quality control pathway and thus has retained its signal peptide, we performed a western blot of the cytosolic proteins with an antibody directed against the N-terminal signal peptide of PrP (SP-PrP) [27]. CyPrP from WT PrPV, PrP F198SV, D202NV, Q217RV, and Q212PM all contained a small amount of SP-CyPrP, whereas increasing the concentration of WT PrP cDNA to 10 or 20 microg generated easily detectable SP-CyPrP (Fig. 4C). Given that the CyPrP easily detected with the 3F4 antibody migrates at 25 kDa, the expected size for PrP that would have lost both its N-terminus and C-terminus signal peptides, these results indicate that GSS PrP mutants generate considerably more retrotranslocated CyPrP than SP-CyPrP.
###end p 54
###begin title 55
###xml 71 76 <span type="species:ncbi:9606">human</span>
All GSS-associated PrP mutants lose their anti-Bax function in primary human neurons
###end title 55
###begin p 56
###xml 318 325 318 325 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5A</bold>
###xml 318 325 318 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g005"><bold>Fig. 5A</bold></xref>
###xml 414 421 414 421 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5A</bold>
###xml 414 421 414 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g005"><bold>Fig. 5A</bold></xref>
###xml 451 458 451 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5B</bold>
###xml 451 458 451 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006647-g005"><bold>Fig. 5B</bold></xref>
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 303 308 <span type="species:ncbi:9606">human</span>
###xml 824 829 <span type="species:ncbi:9606">human</span>
###xml 947 952 <span type="species:ncbi:9606">human</span>
To determine the anti-Bax function of GSS-associated PrP mutants in a neuronal cell type, we assessed the ability of the GSS-associated mutants against Bax-mediated cell death in primary human neurons. None of the GSS-associated PrP mutants induced cell death assessed by condensed chromatin in primary human neurons (Fig. 5A). However, these mutants also did not protect against Bax-mediated condensed chromatin (Fig. 5A) or TUNEL positive staining (Fig. 5B) compared to WT PrP's. Because all mutants lost their ability to inhibit the downstream Bax-mediated events, these results inferred that the mutants were also unable to inhibit caspase activation. The cytosolic level of GSS PrP mutants could not be assessed in these cells because of the very low transfection efficiency and the high endogenous level of PrP in the human primary neurons. Nevertheless, these results show the loss of anti-Bax function in the GSS-associated PrP mutants in human primary neurons.
###end p 56
###begin title 57
###xml 71 76 <span type="species:ncbi:9606">human</span>
All GSS-associated PrP mutants lose their anti-Bax function in primary human neurons.
###end title 57
###begin p 58
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 423 424 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 814 815 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 541 546 <span type="species:ncbi:9606">human</span>
A. Percentage of cell death assessed by condensed chromatin in human neurons transfected with pBud-EGFP or pBud-EGFP-Bax (control), pBud-EGFP/PrP or PrP mutants, and pBud-EGFP-Bax/PrP or PrP mutants carrying a methionine (M) or a valine (V) at codon 129. Data represent the mean+/-SEM of three independent experiments. At least 300 cells were counted for each condition. * indicates a statistically significant difference (p</=0.05) compared to the control. B. Percentage of apoptotic cells displaying DNA fragmentation assessed by TUNEL in human neurons transfected with pBud-EGFP-Bax (control), pBud-EGFP-Bax/PrP, or pBud-EGFP-Bax/PrP mutants. Data represent the mean+/-SEM of three independent experiments. At least 150 cells were counted for each condition. * indicates a statistically significant difference (p</=0.05) compared to the control.
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Roucou2">[18]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 1407 1411 1407 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-DiarraMehrpour1">[14]</xref>
###xml 1438 1439 1438 1439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1446 1447 1446 1447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1457 1458 1457 1458 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1469 1470 1469 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1573 1574 1573 1574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1581 1582 1581 1582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1589 1590 1589 1590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1600 1601 1600 1601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1676 1677 1676 1677 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 2257 2261 2257 2261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Kagawa1">[38]</xref>
###xml 2263 2267 2263 2267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Wolf1">[39]</xref>
###xml 137 142 <span type="species:ncbi:9606">human</span>
###xml 601 606 <span type="species:ncbi:9606">human</span>
###xml 944 949 <span type="species:ncbi:9606">human</span>
###xml 2087 2092 <span type="species:ncbi:9606">human</span>
###xml 2393 2398 <span type="species:ncbi:9606">human</span>
###xml 2451 2456 <span type="species:ncbi:9606">human</span>
In this manuscript, we examined the anti-Bax function of GSS-associated PrP mutants. WT PrP inhibits the first step of Bax activation in human primary neurons and in MCF-7 cells [18]. We previously have shown that eleven CJD-associated PrP mutants with a methionine at codon 129, partially or completely lost their anti-Bax function but that this loss of function could be rescued by co-expressing the CJD mutant PrP with WT CyPrP or its cognate mutant CyPrP [31]. We had also tested the GSS-associated A117V mutant and determined that this mutant retained its anti-Bax function in MCF-7 cells and in human neurons. This suggested that GSS-associated mutants could retain their anti-Bax function and that the retention of this protective function might be relevant to the longer duration of GSS diseases. However, none of the eight additional GSS PrP mutants studied here prevented Bax-mediated DNA condensation or DNA fragmentation in primary human neurons. Because endogenous PrP is highly expressed in these neuron cultures, the results indicate that the GSS-associated mutants, similar to the CJD-associated mutants, have a dominant effect over WT PrP with respect to the anti-Bax function. We also confirmed the loss of anti-Bax function in MCF-7 cells. These cells do not contain detectable levels of endogenous PrP under normal culture conditions, thus eliminating possible effects of endogenous PrP [14]. In the MCF-7 cells, P102LM, P105LV, Y145stopM, and Q212PM could not inhibit Bax-mediated condensed chromatin. However, four of the GSS-associated mutants, F198SV, D202NV, P102LV and Q217RV, prevented Bax-mediated condensed chromatin. However, except for the P102LV, these mutants did not inhibit caspase activation, a step that is upstream of chromatin condensation in the Bax-activated death pathway. The results indicated that these mutants simply delayed the cell death pathway because, in addition to the caspase activation in condensed chromatin positive cells, some transfected cells showed caspase activation in non-condensed chromatin positive cells. In contrast to human neurons, the MCF-7 cells lack the Casp3 gene and thus do not undergo DNA fragmentation although condensation of chromatin occurs through Casp6 and Casp7 activation [38], [39]. The difference in cell death pathways is likely the reason for the slight difference in the results between MCF-7 cells and human neurons. Therefore, we conclude from the results in human neurons and in MCF-7 cells that the anti-Bax function of PrP mutants is not associated with the long duration of the GSS prion disease.
###end p 60
###begin p 61
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 455 458 455 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V/M</sup>
###xml 465 466 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 476 477 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 669 673 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Zanusso1">[44]</xref>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Lorenz1">[45]</xref>
###xml 721 722 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sup>
###xml 1409 1413 1409 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Mishra1">[41]</xref>
###xml 1415 1419 1415 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Singh1">[42]</xref>
###xml 1421 1425 1421 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Zaidi1">[46]</xref>
###xml 1708 1712 1708 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Mishra1">[41]</xref>
###xml 1848 1852 1848 1852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-LarochePierre1">[30]</xref>
###xml 2219 2227 2219 2227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2232 2239 2232 2239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2248 2252 2248 2252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Singh1">[42]</xref>
###xml 2254 2258 2254 2258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Zaidi1">[46]</xref>
###xml 2259 2263 2259 2263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Liemann1">[53]</xref>
###xml 2390 2394 2390 2394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jodoin1">[31]</xref>
###xml 2590 2594 2590 2594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Graner1">[54]</xref>
###xml 2595 2599 2595 2599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Lopes1">[57]</xref>
We also show in this paper that the loss of GSS mutants in inhibiting Bax-mediated condensed chromatin results from the inability of these mutants to generate CyPrP in MCF-7 cells. As shown previously with the eleven CJD-associated PrP mutants [31], the level of CyPrP generated from the GSS-associated mutants was inversely proportional to the level of Bax-mediated condensed chromatin in MCF-7 cells. We observed severely depressed CyPrP levels in P102LV/M, P105LV, Y145stopM. The results with PrP Y145stop are consistent with others that show that PrP Y145stop has a short half-life and accumulates in the nucleus, ER, and Golgi but not significantly in the cytosol [44], [45]. We also observed weak levels of Y145stopM mostly in the nuclear fraction. In those mutants that did generate detectable CyPrP, most of the CyPrP likely resulted from retrotranslocation because CyPrP migrated at the expected size for deglycosylated PrP lacking the N-terminal or C-terminal signal peptides. Retention of the signal peptides would show a protein migrating at 28 to 30 kDa rather than at 23-25 kDa as we observe. Furthermore, western blots of CyPrP with anti-signal peptide antiserum gave only a weak signal compared to that obtained with the anti-PrP 3F4 antibody. The anti-Bax function could have been influenced also by the aggregation of CyPrP, a condition detected in GSS mutants expressed in other cell types [41], [42], [46]. However, we did not observe any detergent insoluble CyPrP indicating that aggregation was not significant in our experimental conditions. The inability of the Q212P mutant to prevent Bax-mediated condensed chromatin, despite generating significant levels of CyPrP (our results and [41]), was consistent with our previous studies showing that proline disruption of PrP's helix 3 structure inhibits PrP's anti-Bax function [30]. The consequences of defective retrotranslocation or loss of the pre-emptive quality control pathway in these mutants will need to be examined more closely. It is generally assumed that familial PrP mutations affect the folding and the stability of the mutants compared to WT PrP and this has been experimentally demonstrated for P102L, F198S, and Q217R PrP mutants in vitro and in vivo studies [42], [46]-[53]. We have shown that CJD mutants accumulate to normal levels on the cell surface while undergoing defective retrotranslocation [31]. Several signaling functions are attributed to cell surface PrP and could be affected by misfolded mutant PrP that have escaped the retrotranslocation or the pre-emptive quality control pathways [54]-[57].
###end p 61
###begin p 62
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 310 311 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 519 520 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Singh1">[42]</xref>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 741 745 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Jin1">[43]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Lin1">[26]</xref>
###xml 1107 1111 1107 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-LarochePierre1">[30]</xref>
###xml 1122 1123 1122 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1130 1131 1130 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
###xml 1142 1143 1142 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sup>
Most importantly, we observed that the GSS-associated mutants that generated significant levels of CyPrP and prevented condensed chromatin could not prevent caspase activation. Therefore, the CyPrP generated from these GSS-associated PrP mutants did not have normal anti-Bax function. Indeed, the F198SV, Q217RV, and D202NV mutants generated as much CyPrP as WT PrPV and while this level was sufficient in preventing Bax-mediated caspase activation in WT PrP, it was not in mutant PrPs. Others have shown that PrP Q217RV escapes the ER quality control and accumulates as an abnormally folded form in the post-Golgi compartment of neuroblastoma cells [42]. Consistent with our observations, a portion of PrP Q217RV accumulates in the cytosol [43]. Because we have previously demonstrated that CyPrP is the main form of PrP with the anti-Bax function [26], we conclude that the mutant CyPrP generated from these three mutants are less efficient at inhibiting the Bax activation pathway than the WT PrP. Previously, we have shown that the helix 3 is necessary and sufficient to inhibit Bax-mediated cell death [30]. The F198SV, Q217RV, and D202NV location in helix 3 is consistent with the observed loss of anti-Bax function in these mutants, despite their ability to generate CyPrP. Therefore, the loss of anti-Bax function in PrP mutants can occur through two mechanisms: low levels of CyPrP through decreased retrotranslocation or pre-emptive quality control and loss in anti-Bax activity for those mutants that can generate CyPrP.
###end p 62
###begin p 63
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Zanusso1">[44]</xref>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Lorenz1">[45]</xref>
###xml 504 508 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gu1">[58]</xref>
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Lee1">[60]</xref>
###xml 615 619 615 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Juanes1">[61]</xref>
###xml 705 709 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gu1">[58]</xref>
###xml 779 783 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Crozet1">[62]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gu1">[58]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gabus1">[63]</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Gabus2">[64]</xref>
###xml 921 925 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Crozet1">[62]</xref>
###xml 927 931 927 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006647-Mange1">[65]</xref>
We found it interesting to observe significant amounts of PrP in the nuclear fraction from Wt PrP and most mutant PrP-transfected cells. We can exclude the possibility of contaminating endoplasmic reticulum membranes in the nuclear fraction since BiP is not detected in the nuclear proteins. Possibly, nuclear PrP was translocated from the cytosol to the nucleus. Others have reported fluorescent-tagged PrP and C-terminally truncated forms of PrP in the nuclear and perinuclear compartments [44], [45], [58]-[60]. Nuclear localization was also observed for CyPrP generated by alternative initiation of translation [61]. Two independent nuclear localization signals (NLS) in full length PrP were proposed [58] but CyPrP translocates to the nucleus independently of these two NLS [62]. The nuclear PrP possibly occurs only under stress conditions [58]. Interestingly, PrP interacts with DNA, RNA [63], [64], and chromatin [62], [65] and may be involved in a yet unidentified function in the nuclear compartment. Once this function is determined, it will be interesting to assess the effect of nuclear mutant PrP. However, the level of nuclear PrP did not correlate with the level of condensed chromatin and thus is unlikely to be involved in the anti-Bax function.
###end p 63
###begin p 64
In conclusion, we have excluded the possibility that the retention of PrP's anti-Bax function in GSS-associated mutants could be responsible for the longer duration of GSS disease relative to CJD. However, the fact that nineteen different single point mutations of the prion protein associated with CJD, GSS and FFI significantly inhibit PrP's anti-Bax function suggests that both trafficking and structural problems arise with mutations in the PrP.
###end p 64
###begin p 65
We are grateful to the Birth Defects Research Laboratory (University of Washington, Seattle, WA, USA) for providing conceptal tissue for research.
###end p 65
###begin title 66
References
###end title 66
###begin article-title 67
###xml 105 110 <span type="species:ncbi:9606">human</span>
Gerstmann-Straussler-Scheinker syndrome,fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies.
###end article-title 67
###begin article-title 68
Gerstmann-Straussler-Scheinker disease and the Indiana kindred.
###end article-title 68
###begin article-title 69
The transmissible spongiform encephalopathies.
###end article-title 69
###begin article-title 70
Sporadic and familial CJD: classification and characterisation.
###end article-title 70
###begin article-title 71
Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene.
###end article-title 71
###begin article-title 72
Neuropathology of Gerstmann-Straussler-Scheinker disease.
###end article-title 72
###begin article-title 73
Cellular prion protein neuroprotective function: implications in prion diseases.
###end article-title 73
###begin article-title 74
The cellular prion protein (PrP(C)): its physiological function and role in disease.
###end article-title 74
###begin article-title 75
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Axotomy-induced motoneuron death is delayed in mice overexpressing PrPc.
###end article-title 75
###begin article-title 76
The Role of the Octarepeat Region in Neuroprotective Function of the Cellular Prion Protein.
###end article-title 76
###begin article-title 77
###xml 42 57 <span type="species:ncbi:10090">transgenic mice</span>
Doppel-induced cerebellar degeneration in transgenic mice.
###end article-title 77
###begin article-title 78
###xml 52 57 <span type="species:ncbi:10090">Mouse</span>
Expression of Amino-Terminally Truncated PrP in the Mouse Leading to Ataxia and Specific Cerebellar Lesions.
###end article-title 78
###begin article-title 79
###xml 37 41 <span type="species:ncbi:10090">Mice</span>
Increased Sensitivity to Seizures in Mice Lacking Cellular Prion Protein.
###end article-title 79
###begin article-title 80
###xml 23 28 <span type="species:ncbi:9606">human</span>
Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death.
###end article-title 80
###begin article-title 81
Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR.
###end article-title 81
###begin article-title 82
Overexpression of PrPC and its antiapoptosis function in gastric cancer.
###end article-title 82
###begin article-title 83
Silencing of Prion Protein Sensitizes Breast Adriamycin-Resistant Carcinoma Cells to TRAIL-Mediated Cell Death.
###end article-title 83
###begin article-title 84
###xml 74 79 <span type="species:ncbi:9606">human</span>
Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells.
###end article-title 84
###begin article-title 85
###xml 85 90 <span type="species:ncbi:9606">human</span>
Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons.
###end article-title 85
###begin article-title 86
###xml 23 28 <span type="species:ncbi:9606">Human</span>
Prion Protein Protects Human Neurons against Bax-mediated Apoptosis.
###end article-title 86
###begin article-title 87
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Widespread elimination of naturally occurring neuronal death in Bax-deficient mice.
###end article-title 87
###begin article-title 88
Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes.
###end article-title 88
###begin article-title 89
Mechanisms of caspase activation and inhibition during apoptosis.
###end article-title 89
###begin article-title 90
Endonuclease G is an apoptotic DNase when released from mitochondria.
###end article-title 90
###begin article-title 91
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor.
###end article-title 91
###begin article-title 92
Cytosolic prion protein is the predominant anti-Bax prion protein form: exclusion of transmembrane and secreted prion protein forms in the anti-Bax function.
###end article-title 92
###begin article-title 93
Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation.
###end article-title 93
###begin article-title 94
Protection from cytosolic prion protein toxicity by modulation of protein translocation.
###end article-title 94
###begin article-title 95
Substrate-Specific Translocational Attenuation during ER Stress Defines a Pre-Emptive Quality Control Pathway.
###end article-title 95
###begin article-title 96
Helix 3 is necessary and sufficient for prion protein's anti-Bax function.
###end article-title 96
###begin article-title 97
###xml 65 70 <span type="species:ncbi:9606">Human</span>
Defective Retrotranslocation Causes Loss of Anti-Bax Function in Human Familial Prion Protein Mutants.
###end article-title 97
###begin article-title 98
###xml 43 48 <span type="species:ncbi:9606">human</span>
Processing of amyloid precursor protein in human primary neuron and astrocyte cultures.
###end article-title 98
###begin article-title 99
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins.
###end article-title 99
###begin article-title 100
Prion protein amyloidosis.
###end article-title 100
###begin article-title 101
Genetic prion disease: the EUROCJD experience.
###end article-title 101
###begin article-title 102
Phenotypic variability of Gerstmann-Straussler-Scheinker disease is associated with prion protein heterogeneity.
###end article-title 102
###begin article-title 103
Prion protein with Y145STOP mutation induces mitochondria-mediated apoptosis and PrP-containing deposits in vitro.
###end article-title 103
###begin article-title 104
Deficiency of Caspase-3 in MCF7 Cells Blocks Bax-mediated Nuclear Fragmentation but not Cell Death.
###end article-title 104
###begin article-title 105
Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation.
###end article-title 105
###begin article-title 106
CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription.
###end article-title 106
###begin article-title 107
Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders.
###end article-title 107
###begin article-title 108
Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation.
###end article-title 108
###begin article-title 109
The Chaperone Protein BiP Binds to a Mutant Prion Protein and Mediates Its Degradation by the Proteasome.
###end article-title 109
###begin article-title 110
Proteasomal Degradation and N-terminal Protease Resistance of the Codon 145 Mutant Prion Protein.
###end article-title 110
###begin article-title 111
Cellular Phenotyping of Secretory and Nuclear Prion Proteins Associated with Inherited Prion Diseases.
###end article-title 111
###begin article-title 112
Characterization of the F198S prion protein mutation: enhanced glycosylation and defective refolding.
###end article-title 112
###begin article-title 113
###xml 69 74 <span type="species:ncbi:9606">Human</span>
The Effect of Disease-associated Mutations on the Folding Pathway of Human Prion Protein.
###end article-title 113
###begin article-title 114
Pathogenic mutations located in the hydrophobic core of the prion protein interfere with folding and attachment of the glycosylphosphatidylinositol anchor.
###end article-title 114
###begin article-title 115
Mutant and infectious prion proteins display common biochemical properties in cultured cells.
###end article-title 115
###begin article-title 116
###xml 41 46 <span type="species:ncbi:9606">human</span>
Prion protein NMR structure and familial human spongiform encephalopathies.
###end article-title 116
###begin article-title 117
###xml 70 75 <span type="species:ncbi:9606">human</span>
Familial mutations and the thermodynamic stability of the recombinant human prion protein.
###end article-title 117
###begin article-title 118
Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form.
###end article-title 118
###begin article-title 119
###xml 59 64 <span type="species:ncbi:9606">Human</span>
Influence of Amino Acid Substitutions Related to Inherited Human Prion Diseases on the Thermodynamic Stability of the Cellular Prion Protein.
###end article-title 119
###begin article-title 120
Cellular prion protein binds laminin and mediates neuritogenesis.
###end article-title 120
###begin article-title 121
Cellular prion protein transduces neuroprotective signals.
###end article-title 121
###begin article-title 122
Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection.
###end article-title 122
###begin article-title 123
Interaction of Cellular Prion and Stress-Inducible Protein 1 Promotes Neuritogenesis and Neuroprotection by Distinct Signaling Pathways.
###end article-title 123
###begin article-title 124
Identification of cryptic nuclear localization signals in the prion protein.
###end article-title 124
###begin article-title 125
Subcellular localization of prion proteins and the 37 kDa/67 kDa laminin receptor fused to fluorescent proteins.
###end article-title 125
###begin article-title 126
Internalization of mammalian fluorescent cellular prion protein and N-terminal deletion mutants in living cells.
###end article-title 126
###begin article-title 127
Biosynthesis of prion protein nucleocytoplasmic isoforms by alternative initiation of translation.
###end article-title 127
###begin article-title 128
The truncated 23-230 form of the prion protein localizes to the nuclei of inducible cell lines independently of its nuclear localization signals and is not cytotoxic.
###end article-title 128
###begin article-title 129
The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein.
###end article-title 129
###begin article-title 130
###xml 108 113 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1.
###end article-title 130
###begin article-title 131
Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin.
###end article-title 131
###begin p 132
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 132
###begin p 133
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the National Institutes for Health (1RO1 NS-40431), the Canadian Institutes of Health Research (MOP 89376), and the Fonds de Recherche en Sante du Quebec. The Birth Defects Research Laboratory (University of Washington, Seattle, WA, USA) is funded by NIH HD 000836. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 133

